Topic
Allergan
Allergan is a drug company, best known for Botox, and these podcasts covered its history of deals, patent fights and takeovers. On the podcast Approved, Alex Kesin said Allergan bought Inamed for over $3 billion in 2006, and sold its generics business to Teva for $40 billion in 2016.
Matthew Pech said Valeant launched an unsolicited hostile bid for Allergan in April 2014, and that AbbVie agreed in June 2019 to buy it for $63 billion. Kesin also said Allergan assigned six Restasis patents to the Saint Regis Mohawk Tribe in 2017. Luke Timmerman told The Long Run that the aim was to block generic challengers.
15 facts from 2 episodes, in date order. These are what speakers said on the shows, each linked to the moment it was said. They aren't independently verified.
1991
Accounts of Allergan's price for Oculinum conflict: the press and Gavin Herbert said $9 or $10 million, a later Allergan CEO said $28 million, and Alan Scott said $4.5 million.
“A later CEO of Allergan swears it's $28 million. Alan Scott says he sold it for $4.5 million.”
Matthew Pech · Allergan: Botox, Rogue Scientists, and the Ultimate Beauty Franchise, 1:20:49
1998
In his first year as Allergan CEO, David Pyatt cut overhead headcount by 22% and redirected the savings to the sales force.
“In his freshman year as CEO, Pyatt slashes Allergan's overhead headcount by 22%.”
Alex Kesin · Allergan: Botox, Rogue Scientists, and the Ultimate Beauty Franchise, 1:52:40
2006
In 2006 Allergan bought Inamed for over $3 billion, gaining Juvederm fillers and breast implants for its aesthetics lineup.
“Their foundational purchase in this playbook kicks off in 2006 when they drop over $3 billion to buy Inimed.”
Alex Kesin · Allergan: Botox, Rogue Scientists, and the Ultimate Beauty Franchise, 1:59:58
2008
Allergan won FDA approval for the eyelash-growth product Latisse in December 2008, after clinicians noticed longer eyelashes as a side effect of a glaucoma drop.
“and boom, boom, boom, in December 2008, they had approval for Latisse.”
Matthew Pech · Allergan: Botox, Rogue Scientists, and the Ultimate Beauty Franchise, 1:55:27
2011
According to Alex Kesin, Allergan spent about $60 million around 2011 to get a new potency assay accepted by the FDA to replace the mouse lethality test.
“I remember reading that in 2011, they spent like $60 million to get a new assay for the FDA.”
Alex Kesin · Allergan: Botox, Rogue Scientists, and the Ultimate Beauty Franchise, 2:59:17
2013
By 2013, therapeutic uses accounted for 54% of Botox sales across about 25 medical conditions.
“by 2013, right towards the end of his term as CEO, Therapeutics was accounting for 54 % of all Botox sales across roughly 25 distinct medical conditions.”
Alex Kesin · Allergan: Botox, Rogue Scientists, and the Ultimate Beauty Franchise, 1:54:08
2014
Valeant Pharmaceuticals launched an unsolicited hostile takeover bid for Allergan in April 2014.
“In April 2014, a company called Valeant Pharmaceuticals launches an unsolicited, hostile takeover attempt of Allergan”
Matthew Pech · Allergan: Botox, Rogue Scientists, and the Ultimate Beauty Franchise, 2:04:49
2014
Bill Ackman's Pershing Square amassed a 9.7% stake in Allergan worth about $3.2 billion, with Valeant secretly co-funding the effort.
“Bill Ackman's Pershing Square fund had quietly amassed a 9.7 % stake in Allergan, worth about $3.2 billion through a vehicle called PS Fund One.”
Alex Kesin · Allergan: Botox, Rogue Scientists, and the Ultimate Beauty Franchise, 2:08:48
2014
On November 17, 2014, the sale of Allergan to Actavis was announced at $219 a share, about $66 billion total.
“On November 17, 2014, the sale of Allergan to Actavis was announced at $219 a share, about $66 billion total.”
Alex Kesin · Allergan: Botox, Rogue Scientists, and the Ultimate Beauty Franchise, 2:17:52
2016
On April 4, 2016, the US Treasury issued a temporary regulation targeting serial tax inversions, which undercut the planned Pfizer-Allergan merger.
“On April 4th of 2016, the Treasury stepped in and issued a temporary regulation aimed pretty much squarely of what Allergan was doing.”
Alex Kesin · Allergan: Botox, Rogue Scientists, and the Ultimate Beauty Franchise, 2:42:15
2016
In August 2016 Allergan sold its global generics business to Teva for $40 billion.
“in August, he takes Allergan's entire global generics business and punts it over to Teva for $40 billion.”
Alex Kesin · Allergan: Botox, Rogue Scientists, and the Ultimate Beauty Franchise, 2:43:28
2017
Luke Timmerman said Allergan transferred patents to an Indian tribe with sovereign immunity to prevent generic companies from challenging them in court, to protect a dry eye franchise.
“Allergan comes out with this patent gambit where they transferred over to an Indian tribe with sovereign immunity so that generic companies can't challenge their patents in court.”
Luke Timmerman · Ep3: George Yancopoulos, 0:45:32
2017
In 2017 Allergan assigned six Restasis patents to the Saint Regis Mohawk Tribe, paying $13.5 million up front and a little over $15 million a year, to try to use tribal sovereign immunity against patent review.
“Allergan assigns them all six key Orange Book Restasis patents and pays them $13.5 million up front and a little over $15 million a year.”
Alex Kesin · Allergan: Botox, Rogue Scientists, and the Ultimate Beauty Franchise, 2:36:31
2017
Federal judge William Bryson invalidated the Restasis patents and wrote that sovereign immunity should not be a purchasable commodity for private entities.
“Sovereign immunity should not be treated as a monetizable commodity that can be purchased by private entities as part of a scheme to evade their legal responsibilities.”
Matthew Pech · Allergan: Botox, Rogue Scientists, and the Ultimate Beauty Franchise, 2:37:23
2019
AbbVie agreed in June 2019 to buy Allergan for $63 billion, a 45% premium to its prior stock price.
“In June of 2019, AbbVie agrees to buy Allergan for $63 billion, representing a 45 % premium over where the stock was trading before.”
Matthew Pech · Allergan: Botox, Rogue Scientists, and the Ultimate Beauty Franchise, 2:51:23